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During the last 20 years, the spread of penicillin- 
resistant and multiresistant Streptococcus pneumoniae has 
become an increasing international problem [ 13. The 
problem in Sweden was, for many years, limited, with 
national incidences well below 5% of strains with 
reduced susceptibility to penicillin, i.e. minimum 
inhibitory concentrations (MIC) 20.12 mg/L [2,3]. 
However, in the early years of the 1990s, the incidence 
figures in Malmohus County in southern Sweden 
increased to 8-15%, [4,5], while the corresponding 
figures for the rest of Sweden have remained at lower 
levels [6-81 (Figure 1). 
In late 1994 and early 1995, the discussions grew 
more intense over whether something could be done 
to halt the increasing incidence of penicillin resistance 
that had been observed in southern Sweden, and 
prevent such an increase in the rest of the country. A 
national expert committee was formed with repre- 
sentatives from the Swedish Institute for Infectious 
Disease Control, the National Board of Health and 
Welfare, the Society of County Medical Officers for 
Communicable Diseases, and independent experts. The 
discussions were soon focused on the spread of resistant 
pneumococci in small children, especially in day-care 
settings. 
National recommendations from the group were 
issued in 1995 [9], outlining possible intervention 
measures against the spread of penicillin-resistant pneu- 
mococci with MIC for penicillin G (PcG) 20.5 mg/L 
(PRP) among small children. The 0.5 mg/L limit was 
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originally chosen to give a margin to the highly resistant 
strains (MIC 22.0 mg/L). Pneumococcal isolates with 
MIC for penicillin 20.5 mg/L have been notifiable by 
Swedish law since 1 January 1996 [lo]. In 1996 and 
1997, 31% and 35%, respectively, of the notified PRP 
in Sweden (population 8.7 million) were reported from 
Malmohus County (population 817 000). 
THE SOUTH SWEDISH PNEUMOCOCCAL INTERVENTION 
PROJECT 
The first large-scale attempt to implement these recom- 
mendations was started in Malmohus County, southern 
Sweden, in March 1995 (the South Swedish Pneumo- 
coccal Intervention Project) [ll]. This project is still 
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Figure 1 Percentage of pneumococcd isolates with 
reduced susceptibility to penicillin (MIC 20.12 mg/L) in 
Malmohus County, southern Sweden, and all Sweden in 
1994-97. The data derive from a survey of the resistance of 
approximately 3000 strains of Sfveptococcus pyagenes, 
Haemophilur inzuenzae and S. pneurnoriiae to a number of 
commonly used antibiotics, performed each year by The 
Swedish Reference Group for Antibiotics (SRGA) [8] .  
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running, and has been followed by similar initiatives in 
most other Swedish counties. 
Since March 1995, all P R P  with MIC for PcG 
2 0.5 mg/L have been directly reported from the three 
microbiology laboratories in the county to the Regional 
Center of Communicable Disease Control (RCCDC) 
in Malmo. Comprehensive retrospective data are avail- 
able from January 1995. 
Whenever an individual with an infection due to 
PRP is identified (‘index case’), the R C C D C  contacts 
the local healthcare center of that patient. The local 
physician is then responsible for securing nasopharyn- 
geal specimens from family members and other close 
contacts (e.g. day-care group) of the index case, in 
order to identify carriers in the surrounding area 
(‘contact cases’). All carriers (index cases as well as 
contact cases) are followed with weekly nasopharyngeal 
cultures, until two consecutive negative specimens have 
been obtained (‘PRP negative’). All control cultures, 
and other healthcare contacts due to the project, are 
free of charge for the individual patient. 
If an identified carrier is a child participating in any 
form of child day care, nasopharyngeal specimens are 
also obtained from the staff and other children in that 
day-care group. If more carriers are found, the screen- 
ing procedures can be extended to the whole day-care 
center. Repeated cultures are then obtained every 1-2 
weeks from the children and staff, until no more 
carriers are identified. Pre-school children who are 
identified as carriers stay away from group day care until 
they are PRP negative. The parents of these children 
are able to stay at home with full reimbursement from 
the social security system, if the day-care cannot be 
arranged in any other way. PRP-carrying school- 
children and adults are recommended to stay away from 
school or work if having an acute respiratory tract 
infection. Parents of PRP-carrying small children are 
urged to have them avoid close indoor contacts with 
other small children or frail elderly people. Outdoor 
play or other activities (shopping, visits to the library, 
etc.) are considered to constitute such a small risk of 
transmission that, in these cases, no limitations are 
recommended. 
EPIDEMIOLOGIC PAl lERNS 
During the period 1 January 1995 to 30 June 3998, 
1545 PRP carriers (1492 individuals) were identified in 
Malmohus County. Of  the 1545 episodes, 642 (41%) 
were in index cases and 903 (59%) in contact cases 
(Figure 2). The pattern of carriage has shown a pro- 
nounced seasonal pattern, with most cases occurring 
during the winter months. The winter seasons 1995-96 
and 1997-98, with more carriers than during the 
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Figure 2 Monthly number of PRP cases in Malmohus County, shown as index cases and contact cases. 
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winter season 1996-97, coincide with high numbers 
of respiratory syncytial virus (RSV) infections among 
young children. 
The largest proportion of carriers has been children 
1-6 years of age (81% of the cases). The index cases 
have dominated in the extremes of ages (younger than 
2 years and older than 65 years), while the contact cases 
have dominated in the older children and young adults. 
Of  the pre-school children, 66% have been attending 
day-care centers and 8% family day care, and 26% have 
been cared for by the parents at home [ I l l .  The other 
cases have, with few exceptions, been elder siblings, 
parents or grandparents of small children. Only 11 cases 
of carriage have been found in day-care staff. This 
could probably be explained by a combination of 
immunity, and less intimate contact with the children 
than that of their parents. 
Altogether, 170 of the approximately 600 day-care 
centers in the county have been screened for P R P  
during the period. The number of P R P  carriers in 
each day-care center has varied within great intervals 
(median 3, interval 1-23), and in half of the day-care 
centers no further PRP carrier was identified. Screen- 
ing cultures were, on average, obtained twice in each 
day-care center, before the day-care center could be 
declared ‘PRP-free’. 
The PRP strains were very unevenly distributed 
over the county and over time. The spread has mainly 
been noted in the most densely populated areas of the 
county. The P R P  strains often appeared in ‘miniature 
epidemics’ around one or a few index cases. Some 
severely ‘affected’ communities have, after intervention 
in a few day-care centers, remained ‘PRP-free’ for an 
extended length of time. In all, 244 day-care inter- 
ventions were performed. The majority (151) took 
place in the three largest cities (Malmo, Lund, and 
Helsingborg). The remaining 93 day-care interventions 
were undertaken in smaller communities, with less than 
50 000 inhabitants. After 39 of these interventions, the 
community remained free from PRP with that specific 
serotype/antibiotic pattern for the remainder of the 
study period. Excluding the most prevailing serotype 
1. Malmo (01-95) 
2. Staffanstorp (03-95) 
3. Vellinge (03-95) 
4. Landskrona (03-95) 
5. Hoganas (04-95) 
6. Lund (04-95) 
8. Kavlinge (06-95) 
9. Trelleborg (08-95) 
10. Helsingborg (09-95) 
12. Lornma (10-95) 
13. Hoor (12-95) 
14. Svalov (01-96) 
15. Svedala (02-96) 
16. Skurup (03-96) 
17. Bjuv (1 2-97) 
7. EsIOV (04-95) 
11. BurlOv (09-95) 
Figure 3 Map of Malmohus County with the most likely routes of clonal spread of PRP serotype 9V The table gives the 
month when the clone was first identified in a community. In the three communities Horby, Sjobo and Ystad, this clone has 
not yet been identified. 
hYV (see below), which was very hard to eradicate, 34 
of 48 day-care interventions resulted in apparent 
eradication of that PRP in the small community. 
The heterogeneous picture with many circulating 
clones (see below) and the fact that many children in a 
single day-care center could be carriers makes monthly 
comparisons difficult. 
SEROGROUPS, M I C  LEVELS A N 0  RESISTANCE PATTERNS 
Serotyping to the group level has been performed in 
1357 of the 1545 strains (87%). Eighteen different 
serotypes/groups have been found. Of  these, 94% 
belonged to the six most common serotypes/groups 9, 
19, 15, 6, 23 and 7 (in that order). These serotyped 
groups are also common among PRP isolates in other 
parts of Europe [12,13], and are often found in small 
children irrespective of penicillin resistance [14,15]. 
When serotype/group and resistance pattern were 
combined, more than 40 different PRP variants were 
observed. Genetic fingerprinting has also confirmed 
that a large number of PRP clones are circulating [16]. 
The large number of different PRP clones suggests that 
these strains have been spreading in the county for a 
long time. 
The largely dominant PRP strain in the county 
during the study period was of serotype 9V, resistant 
to PcG (MIC 0.5-2.0 mg/L) and trimethoprim- 
sulfamethoxazole (632 cases; 47%). A genetic finger- 
printing study of this strain has revealed that it is a 
single specific clone, which also has been found to be 
widespread throughout Europe [17]. This clone was 
probably introduced into the county in late 1994, and 
we have succeeded in following its spread fi-om com- 
munity to comniunity (Figure 3). The same clone has 
also been found in other parts of the country [18]. 
MIC levels for PcG, and resistances to other 
common oral antibiotics are shown in Table 1. The 
strains with the highest MIC levels were all multiply 
antibiotic resistant. Eight of nine strains with PcG MIC 
> 2  mg/L were isolated from families with children 
recently adopted from Hungary (n =3; two families), 
Romania ( n = l ) ,  Poland (n=l),  Russia ( n = l ) ,  Slovakia 
( n = l )  and Vietnam (n=2; one family). Fortunately, 
these strains have not spread outside the family [IY]. 
DURATION OF CARRIAGE 
The duration of carriage has been studied in detail for 
the first 678 individuals in the project [20]. The median 
duration of carriage was 19 (3-267) days. The duration 
of carriage decreased with increasing age, with median 
carriage duration of 30 days in children younger than 
1 year, compared to 14 days in adults. Seventy-two per 
cent of the individuals were PRP-free within 4 weeks, 
88% within 8 weeks, and 94% within 12 weeks. After 
adjusting for age, no difference in duration of carriage 
was noted between different serotypes. Previously 
infection-prone children were carriers for a longer 
period of time, while recent antibiotic consumption 
did not appear to affect the duration ofcarriage [20,21]. 
The PRP were carried for a longer time during the 
winter months (with higher incidences of viral 
respiratory tract infections) than during the summer 
months [20]. 
ERADICATION OF CARRIAGE 
In selected cases, we chose to eradicate the carriage 
with antibiotics [22]. This was considered after at least 
2 (preferably 3) months of carriage, or earlier when 
strong social reasons existed. About 50 children have 
been treated for 1 week with rifampicin (10 ing/kg 
twice a day) in combination with either eiythromycin 
(25 mg/kg twice a day), clindamycin (5 mg/kg three 
times a day), or amoxycillin (20 mg/kg twice a day) 
[22]. In all children except one (primary carrier of a 
rifampicin-resistant strain), the PRP were eradicated 
with these treatment regimens. In twin brothers, PRP 
of the same serotype and resistance pattern were found 
in the nasopharynx several months after treatment and 
two consecutive PRP-negative cultures. Although we 
Table 1 Number of PRP with different MIC levels of penicillin G (PcG) isolated in Malmohus County 1995-98, and 
resistance to trimethoprim-sulfamethoxazole, tetracycline, and erythromycin 
MIC of PcC Number of No other Trimethoprimn- 
( " d L )  strains resistance sulfamethoxazole Tetracycline Erythromycin 
0.5 553 246 248 182 79 
1 .o 664 43 567 182 87 
2.0 319 6 295 47 31 
4.0 7 0 7 6 6 
16.0 2 0 2 1 2 
Total 1545 29 5 1119 418 205 
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have not experienced it, we know of at least one 
Swedish case with confirmed development of rifam- 
picin resistance during treatment for eradication (R. 
Alsterlund, personal communication), and this pheno- 
menon has also been described from South Africa [23]. 
Due to the high risk of development of rifampicin 
resistance, treatment for eradication is advisable only in 
well-selected cases. This should be done only in areas 
with a very low PRP prevalence, or when actions have 
been taken to limit the spread of PRP in the surround- 
ing population (as has been done in southern Sweden). 
A controlled, randomized study on the efficacy of 
different treatment regimens, as well as assessment of 
long-term PRP negativity after treatment, is under way. 
EFFORTS TO REDUCE ANTIBIOTIC CONSUMPTION 
Efforts to reduce antibiotic consumption have been 
channeled through the Swedish Strategic Program for 
The Rational Use ofAntimicrobia1 Agents and Surveil- 
lance of Resistance (STRAMA), which was initiated in 
1994 [24]. A national STRAMA group was formed, 
and included specialists in infectious diseases, micro- 
biology, general practice, otorhinolaryngology, and 
pediatrics. The national expert group also included 
representatives of the Swedish Institute for Infectious 
Disease Control, the Swedish Medical Products 
Agency, the National Board on Health and Welfare, the 
National Corporation of Pharmacies, the Swedish 
Veterinary Agency, the Society of County Medical 
Officers of Communicable Diseases, and the Swedish 
Network for Pharmacoepidemiology (NEPI). Through 
the assistance of the national STRAMA group, regional 
STRAMA groups have been formed in all Swedish 
counties, chaired by the County Medical Officer of 
Communicable Diseases. These regional groups include 
specialists from the same medical fields as the national 
group [34]. 
The primary goal of both the national and the 
regional STRAMA groups is a reduction of inappro- 
priate antibiotic usage through increased knowledge 
and understanding of the relationship between anti- 
biotic consumption and bacterial resistance, by both the 
medical profession and the general public. Surveillance 
programs of antibiotic resistance have been developed 
and supported, at both national and local levels. The 
increasing incidences of PRP have been the main 
target, and the program has therefore mainly focused 
on the treatment of upper respiratory tract infections 
and antibiotic usage in pre-school children. The regional 
STRAMA groups have, after identifj.ing the problems 
in the county, tried to influence physicians to improve 
diagnostic procedures and change prescribing patterns 
of antibiotics [24]. 
Specific activities have included symposia arranged 
for the regional groups. An information leaflet on 
respiratory tract infections, antibiotics and resistance 
has been distributed to all Swedish health care centers. 
The media coverage of both the STRAMA work and 
the day-care interventions has been extensive, and this 
has further increased awareness of the problems with 
resistance and antibiotic overuse [24]. 
ANTIBIOTIC SALES STATISTICS 
Statistics on antibiotic sales at the national and county 
levels are available from the ongoing prescription survey 
of the Corporation of Swedish Pharmacies, both as 
defined daily doses (DDD) per 1000 inhabitants, and as 
number of prescribed items per 1000 inhabitants and 
year. In the period 1980-95, the survey was based 
on a sample of one in 25 prescriptions. From 1996 
onwards, all prescriptions served have been registered. 
From 1993 to 1997, the outpatient antibiotic 
utilization in Sweden was reduced by 34%, with the 
reduction especially evident for macrolides and peni- 
cillin V (Figure 4) [24,25]. This reduction has been 
more prominent in Sweden than in the other Nordic 
countries. In Malmohus County the outpatient pre- 
scription of antibiotics has, during the 1990s, been 
20-30% higher than the national figures. The county 
has followed the national trend, with a 26% decrease in 
outpatient antibiotic sales between 1993 and 1997 [35]. 
DISCUSSION 
In the 'Swedish intervention model', we have applied 
traditional communicable disease actions (contact 
tracing and isolation) to a new phenomenon (antibiotic 
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Figure 4 Antibiotic sales statistics for selected oral 
antibiotics expressed in defined daily doses (DDD) per 1000 
inhabitants in Sweden [24,25]. TMP/SMX. trimethoprim- 
sulfamethoxozole. 
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resistance). Most Swedish counties have adopted the 
recommendations of the national expert committee, 
which formed the basis for the South Swedish Pneumo- 
coccal Intervention Project. The measures are under 
continuing evaluation, and the final conclusions have 
not yet been drawn. The model is internationally 
unique, since the efforts in other countries have been 
limited to resistance surveillance and actions against the 
overuse of antibiotics [26,27]. 
The studies that have been referred to in this paper 
[11,17,20-221, as well as others that are underway, are 
aimed at forming a scientific basis for evaluation of 
active intervention measures against antibiotic resistance 
in the community. Factors influencing the spread (age 
distribution and density of population, day-care patterns, 
antibiotic consumption, incidence of viral infections, 
prevailing PRP serotypes, resistance patterns, etc.) and 
detection of PRP (healthcare contacts, indications for 
nasopharyngeal culture) are numerous. Several recent 
day-care outbreaks in a community may influence the 
inclination of both doctors and parents to have naso- 
pharyngeal cultures taken. During the three winter 
seasons in which the measures have so far been imple- 
mented, the monthly numbers of PRP cases have also 
correlated very well with the number of diagnosed 
RSV cases. Furthermore, since the active communicable 
disease control interventions have been implemented 
simultaneously with the so-far successful attempts to 
decrease antibiotic consumption, it is impossible to 
determine the impact of each single measure on the 
resistance situation, or of other events. 
Comparisons with other parts of the country, 
where only measures aiming at reducing the antibiotic 
coiisumption have been taken, are hard to make. 
Southern Sweden is geographically more exposed to 
imported strains than other parts of the country, and 
has had a relatively higher PRP prevalence, for a longer 
period of time, and with a large number of circulating 
PRP clones. Comparative stuches on a day-care level 
would, however, be feasible, and are underway. 
In an epidemiologic model, based on the experi- 
ences from a large number of countries, Baquero has 
shown that the frequency of penicillin resistance slowly 
increases to a threshold of about 8%. Thereafter, the 
levels rapidly increase to 20-40%, or even higher [28]. 
Actions to limit the spread of resistant isolates should 
therefore be taken as early as possible [29]. This inter- 
national experience strongly demands action. The 
impression that circulating PRP strains have disappeared 
(for good?) from many smaller communities where they 
were once established, and that the trend of increasing 
PRP incidence seems to have been halted, indicates 
that the measures have affected the PRP epidemiology 
in southern Sweden. 
In the long run, the rather radical measures that are 
now being implemented in Sweden could probably not 
be maintained. With these actions, we hope to bridge 
the gap until reduced antibiotic consumption has had 
its full impact. Much hope is also put on the next 
generation of conjugated pneumococcal vaccines, 
which are also immunogenic in small children [30,31]. 
Preliminary data suggest that these vaccines also have 
an influence on the carriage rate in the child population 
[32]. Hopefully, the present actions will be sufzcient to 
avoid a high-prevalence situation until these vaccines 
are fully evaluated and included in the general child 
vaccination program. 
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